The Eteplirsen Approval: Former FDA Officials Weigh In On The Science
Executive Summary
A former CDER director, office director, division director, and supervisory reviewer agreed to comment for the record on the merits of the science that formed the basis of FDA’s accelerated approval of the Duchenne Muscular Dystrophy therapy Exondys 51.
You may also be interested in...
Lilly’s Failed Solanezumab: Could It Get Another Chance In A ‘Silicon Valley’ FDA?
Alzheimer drug’s development was discontinued after third disappointing Phase III trial, but given the kind of FDA commissioner candidates getting meetings with the President, maybe Lilly should reconsider.
Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'
Pink Sheet’s Drug Review Profile looks at US FDA clinical memos opposing approval of Sarepta's Duchenne muscular dystrophy drug eteplirsen, revealing challenges patient advocates and agency face in transforming patient experiences into hard data that can be used for approvals.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.